Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A CRYPTOSPORIDIOSIS POINT-OF-CARE TEST-AND-TREAT STRATEGY IN CHILDREN WITH DIARRHOEA (CryptoT&T)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Global Health EDCTP3
Action type: Research and Innovation actions
Partnership: EDCTP3 (JU-JTI)
Countries involved: Norway,Ethiopia,Mozambique
Call: Advancing point-of-care diagnostics to the market (HORIZON-JU-GH-EDCTP3-2023-02-two-stage, 2023)
Start date: 2025-01-01
End date: 2028-12-31
Duration (months): 48.0
Total project cost (EUR): 4700000.0
EU funding (EUR): 4700000.0
Participants: 4
Project status: SIGNED

Cryptosporidium is an intestinal parasite causing cryptosporidiosis, a prevalent diarrheal disease among young children in low- and middle-income countries. This infection causes approximately 48,000 deaths and the loss of 7.9 million disability-adjusted life-years annually. Despite the existence of a low-cost drug, access to treatment is hindered by the limited availability of affordable, straightforward, point-of-care (POC) diagnostic tests. LED microscopy of auramine-phenol (AP) stained fecal smears has demonstrated promising diagnostic accuracy in detecting cryptosporidiosis. In this project, we will implement a test-and-treat strategy in a stepped-wedge cluster randomized trial. The aim is to assess the clinical effectiveness of LED-AP testing, in conjunction with access to targeted drug treatment, in reducing the duration of cryptosporidiosis-induced diarrhea. We will evaluate diagnostic accuracy, operational issues, cost-effectiveness, and test turnaround times in realistic setting in two Sub-Saharan African (SSA) countries. Additionally, we will investigate whether rectal swab samples can expedite test turnaround times compared to bulk stool samples. This project aligns with the UN Sustainable Development Goal 3 and WHO initiatives to reduce the burden of diarrheal diseases. Effective POC diagnostics and treatment are expected to alleviate diarrhea and reduce long-term complications. The findings will be instrumental in updating current diarrheal treatment guidelines, which primarily advocate for syndromic treatment. The outcomes will be of significant interest to health facility staff, ministries of health in SSA, WHO, and the scientific community. This study will provide crucial data on optimizing LED-AP testing to guide clinical decision-making and targeted treatment, thereby preventing the overuse of antibiotics. The introduction of cryptosporidiosis testing can enhance surveillance of this critical pathogen.

Keywords: led microscopy,cryptosporidium,diarrhoea,children,treatment,rectal swab,cost effectiveness,enteric pathogens,stepped wedge cluster randomized trial,point of care test,nitazoxanide,diagnostic accuracy,targeted treatment of diarrhoea
Entangled Flying Electron Quantum Technology (ELEQUANT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France,United Kingdom,Netherlands,Germany,Japan
Call: EIC Pathfinder Open (HORIZON-EIC-2024-PATHFINDEROPEN-01, 2024)
Start date: 2025-03-01
End date: 2029-02-28
Duration (months): 48.0
Total project cost (EUR): 3495061.25
EU funding (EUR): 3495061.25
Participants: 9
Project status: SIGNED

The ELEQUANT project proposes a paradigm shift in quantum technology by exploiting flying qubits, presenting a transformative alternative to mainstream approaches such a superconducting or semiconducting qubits. While photon-based flying qubits face challenges in real-time manipulation and interaction due to their fast propagation speed and weak photon-photon interaction, ELEQUANT aims to harness the potential of electronic charges for superior scalability and connectivity. Through pioneering research in the manipulation of electronic wavepackets in semiconductor nanostructures, the project strives to achieve the ambitious goal of realizing high-fidelity flying charge qubits and demonstrating entanglement between them. Key objectives include the development of novel quantum materials platforms based on strained Ge and multi-layered graphene. By establishing a comprehensive roadmap for solid-state flying qubit technology, ELEQUANT seeks to accelerate innovation in quantum technology and foster collaborative partnerships with industry stakeholders on a European scale. With a focus on scalability, connectivity, and coherence, ELEQUANT aims to propel quantum technology into a new era of unprecedented capabilities and applications.

Keywords: quantum technology,quantum nanoelectronics,quantum information,flying charge qubits,molecular beam epitaxy
Memorializing Manzikert: Triumph, Loss and Making Sense of a Battle in the Twelfth-Century Mediterranean (MEMANZ)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-01-20
End date: 2028-01-19
Duration (months): 24.0
Total project cost (EUR): 260347.92
EU funding (EUR): 260347.92
Participants: 1
Project status: SIGNED

MEMANZ investigates the construction of the memory of the battle of Manzikert in different literary discourses of the Medieval Mediterranean. The battle took place in the eleventh century between the sultan Alp Arslan of the Great Seljuks and emperor Romanos Diogenes of Byzantium. The capture of Romanos and the Byzantine defeat, the battle precipitated a chain of events that led to the civil war in Byzantium, a Turkic migration to Anatolia and the First Crusade. MEMANZ uses notions of “triumph”, “trauma” and “loss” to demonstrate how educated literati from Eastern Roman, Latin, Seljuk-Arabic and Armenian linguistic spheres constructed the memory of the battle for their own aims and means. A Byzantine princess Anna Komnene used Manzikert to rally Byzantine nobles around the flag of her family. A Crusader bishop William of Tyre used it to justify the onset of the Crusades. A Seljuk-Arabic intellectual Ibn al-Athir used the battle to highlight the agenda of his Ayyubid rulers. Finally, a set of three Armenian historians depicted the battle as a meaningful event in the history of the Armenian community. The project reveals many unknown connections between different narratives about the battle. It demonstrates how a single event produced several cycles of interpretations in four different cultures, and how the later generations of educated people re-shaped the memory for their audiences. MEMANZ demonstrates the multipolarity of collective memory in the Medieval Mediterranean that is not limited to the dichotomy of “East” and “West”. The analysis of the construction of the battle allows better understanding of the nature of ideological dichotomies in the European Mediterranean. It opens a new path for the analysis of ongoing confrontations, some of which still deploy memories of Manzikert in everyday discourse. In collective memory of several groups the battle remains a traumatic event and the understanding of it is important for the future of EU and it’s neighbors

Keywords: byzantium,great seljuks,crusades,armenia,manzikert
NetZeroAICT Digital Contrast for Computerised Tomography Towards Climate Neutral and Sustainable Health Systems (NetZeroAICT)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Ensuring access to innovative, sustainable and high-quality health-care
Action type: Research and Innovation actions
Countries involved: Sweden,Greece,Belgium,Brazil,United Kingdom,United States,Netherlands,Spain,Czechia,France,Poland,Australia
Call: Environmentally sustainable and climate neutral health and care systems (HORIZON-HLTH-2023-CARE-04, 2023)
Start date: 2023-12-01
End date: 2027-11-30
Duration (months): 48.0
Total project cost (EUR): 3791075.0
EU funding (EUR): 3791075.0
Participants: 22
Project status: SIGNED

Computerised Tomography (CT) scan is one of the most common medical imaging performed in healthcare, Each year, 300 million CT scans are performed globally. Of which, around 180M include use of radiocontrast media (RCM). Contrast Enhanced CTs (CECT) create a significant environmental impact, namely: 42,000 tonnes of single use packaging, 900 Tonnes of surgical steel (needles), 90,000 tonnes of plastic tubing and 150,000,000 kWh in energy consumption. These generate on average 9.2 kg of CO2/ scan. In addition, CECTs generates 200,000 tonnes of iodine contamination in water/yr. This is a recognised form of ‘pharmaceutical pollution’. CECTs may also harm patients: needle insertion, toxicity of iodinated RCMs to kidneys (potentially kidney failure) and allergic reactions, which in some cases can be life-threatening. Healthcare systems are responsible for the 4.4% CO2 global emissions (2 Giga tonnes/yr). Of this, ~3 Mega tonnes/yr are generated from CECTs. The EU has declared its NetZero targets of by 2050 through the European Green Deal. We showed feasibility that artificial intelligence (AI, deep learning methods) can extract high level information from non-contrast CT scans and synthesise contrast ‘digitally’. This avoids the need to administer RCM for CECTs. We seek to develop and validate 5 uses cases of CT ’Digital Contrast’ during this Horizon award. By implementing ‘Digital Contrast’ for scans globally, we aim to reduce 30% of the CO2e and iodine RCM waste generated from CECTs by 2033. NetZeroAICT has a grand vision to define a reference framework for scalable development of AI health tools for a future of sustainable health systems. This builds on our prior efforts of AICT consortium, which was established to make CT imaging safer, more efficient, more equitable and more sustainable. NetZeroAICT will accelerate the EU’s trajectory towards NetZero and advance EU’s globally recognized leadership position on Healthcare sustainability.

Keywords: artificial intelligence,medtech,sustainability,radiology,netzero
Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management (HER-CARE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Netherlands,Austria,Cyprus,United Kingdom,Sweden,Spain,France,Germany,United States,Czechia,Australia,Switzerland,Denmark
Call: MSCA Doctoral Networks 2024 (HORIZON-MSCA-2024-DN-01, 2024)
Start date: 2026-01-01
End date: 2029-12-31
Duration (months): 48.0
Total project cost (EUR): 4977813.19
EU funding (EUR): 4697517.24
Participants: 33
Project status: SIGNED

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes. HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling. These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment. HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.

Keywords: breast cancer,early onset cancer,young women,risk stratification,artificial intelligence,machine learning,personalized medicine,cancer detection,statistical modeling,precision oncology
Emotional modelling to enhance learning in games (AMELIA)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Finland,Austria
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-09-01
End date: 2026-02-28
Duration (months): 30.0
Total project cost (EUR): 249618.0
EU funding (EUR): 249618.0
Participants: 3
Project status: CLOSED

A UN Sustainable Development Goal is to ensure inclusive and equitable quality education and promote lifelong learning opportunities for all. The project results contribute to improving the future of education for all and have direct scientific, societal, and technological impacts. Current education solutions are limited to a one-size-fits-all paradigm, unable to support diverse learning needs, and contribute to learning exclusion and gender inequality. State-of-the-art (SOA): Game-based learning environments (GBLEs) bring to bear capabilities that not only shatter physical barriers to education via digital learning, but game mechanics built into GBLEs can be customized and adapted to support diverse learning needs. Game mechanics are important because they sustain learners’ engagement and interest in learning activities, which elicit cognitive processes that water the seeds of learning. Still, more research is needed to develop adaptive game mechanics to support diverse learning needs. The mission of this research is to study interactions between game mechanics and emotions as a non-linear dynamical system and observe the impact of such interactions between diverse learners’ cognition and learning outcomes with GBLEs. In this European Fellowship titled, emotionAl Modelling to Enhance Learning In gAmes (AMELIA), we propose to conduct a mixed multimodal methods study to observe relations between game mechanic interactions and in-game emotions, cognition, and learning outcomes by collecting multiple data channels ranging from think-aloud recordings to neurofunctional measures between gender dimensions. AMELIA will be carried out at Tampere University (host) with supervisor Kristian Kiili and co-supervisor Manuel Ninaus (secondment) at the University of Graz. AMELIA is implemented in collaboration with an international game company called Psyon Games.

Keywords: game based learning environments,instructional design,complex systems,multimodal data
The Journey Matters: Pathway Complexity in Polyplex Formation (POLYPATH)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure -properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2308125.0
EU funding (EUR): 2308125.0
Participants: 1
Project status: SIGNED

A vast number of pathologies have a genetic origin. Yet, using gene therapy to directly intervene at the genetic root remains a rarity within today’s pharmaceutical arsenal. The main hurdles in promoting gene therapy from the lab to the clinic are the complex delivery pathways and biological instability of the therapeutic nucleic acids. Polyplexes, nanoscale coacervates of nucleic acids and (synthetic) polymers, hold the prospect of being highly tunable, scalable and robust transport vehicles and as such a key enabler for gene therapy. Despite years of active research, however, polyplexes have yet to fulfil their claimed potential. Our understanding of polyplex formation and the followed assembly pathways are presently insufficient for the rational design of efficient and selective gene delivery vehicles. Prototypical polyplex formation routes are ill-defined, yielding a broad spectrum of unequilibrated structures. The effect of this structural polydispersity on gene delivery and transfection efficiency is unknown, critically hampering the potency of polyplexes. The aim of POLYPATH is to develop polyplex fabrication routes via controllable and predictable assembly pathways. These routes rely on the in situ growth of the encapsulating polymers in the presence of the nucleic acids and yield temporal, on-demand control of the attractive interactions that drive polyplex formation. With this synthetic control, we will create a systematic, predictable library of structurally well-defined polyplexes. The assembly processes will be elucidated with state-of-the-art time-resolved X-ray scattering and spectrally-resolved NMR relaxometry and diffusometry. To bridge the knowledge gap between polyplex structure and function, we will use fluorescence correlation spectroscopy to directly measure polyplex stability and fate in cellular environments. Ultimately, POLYPATH will provide mechanistic insights that can finally bring functional polyplexes towards the clinic.

Keywords: macromolecular complexes including interactions involving nucleic acids
Soft and biological quantum light sources (SoftQuanta)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Condensed Matter Physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Slovenia
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-11-01
End date: 2030-10-31
Duration (months): 60.0
Total project cost (EUR): 2322923.0
EU funding (EUR): 2322923.0
Participants: 2
Project status: SIGNED

Quantum optics is an exciting and rapidly growing research field with a huge potential in different applications such as quantum communications, computing, sensing, and imaging. One of the most crucial components of any quantum optical device is a source of non-classical light, called a quantum light source. Currently, these sources are almost exclusively based on solid-state inorganic materials, which limits their properties, such as lack of complex geometries and limited tunability. In the past, I have pioneered the use of liquid crystals and biomaterials to make various photonic devices. Notably, I made a laser inside a live human cell. Since then, this pioneering work has been employed in a large number of applications, including tunable light sources, biological sensing, cell barcoding, and imaging. Soft photonic devices have unparalleled properties compared to their solid-state counterparts, such as extremely large tunability, self-assembly of complex structures that are impossible to make by lithography, biocompatibility and even self-healing. Similarly as with microlasers, I propose to make quantum light sources from soft and biological matter. The unique properties of soft materials have the potential to give an unprecedented twist to the field of quantum optics but have been unexplored until now. I propose to develop sources of photon pairs out of liquid crystals. By selecting the appropriate liquid crystal structure, these sources will generate almost arbitrary polarization quantum states of the photon pairs, including entangled photons. Moreover, the quantum states will also be tunable by an electric field. Further, I propose to use single-photon sources in biological materials for novel applications such as cell barcoding and to make a purely biological single-photon source. The novel quantum light sources developed in the SoftQuanta project could have a significant impact on quantum sensing, imaging, communications, and maybe even quantum computing.

Keywords: liquid crystals,ferroelectric nematics,color centers,entangled photons,photon pairs,single photon sources,quantum optics,microscopy,bioimaging,cellular barcoding
Deciphering the genetic basis of chronic kidney disease towards prevention and personalized therapy (GeneCKD)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Israel
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-07-01
End date: 2027-06-30
Duration (months): 60.0
Total project cost (EUR): 1800000.0
EU funding (EUR): 1800000.0
Participants: 1
Project status: SIGNED

Chronic Kidney Disease (CKD) is a public health challenge affecting millions globally. Patients have increased risks of mortality, morbidity, and progression to end-stage kidney disease (ESKD). CKD is often clinically silent, disease mechanisms are unclear and targeted therapies are unavailable. Recent studies support considerable contributions of underappreciated monogenic aetiologies in adults with CKD, suggesting that most inherited kidney diseases remain undiagnosed, untreated and poorly understood. Our overarching objective is to unravel the genetic basis of CKD towards early diagnosis and gene-based therapy. We therefore established the Israeli ESKD genetic cohort and already recruited clinical data and samples from 2,000 participants with ESKD. Our main objectives are: 1) to unravel known and novel CKD genes by interrogating high-risk groups for genetic CKD using next generation sequencing on a population level; 2) to study novel monogenic CKD disease mechanisms by using patient-derived kidney organoids and mutation-specific mouse models. Specifically, we will study a newly identified WDR19 mutation leading to many adult onset-ESKD cases in the Israeli Arab-Druze population; and 3) to develop gene-based targeted therapies for CKD. We will focus initially on monogenic CKD secondary to gain-of-toxic-function mutations in UMOD (encoding uromodulin, a kidney-specific protein). This relatively frequent adult CKD aetiology accounts for 0.5-2% of CKD cases worldwide. Altered uromodulin?s toxic effect is suitable for novel RNA-based therapies. Gene silencing of uromodulin with antisense oligonucleotides will be performed and studied, using a patient-derived in vitro model as well as a Umod mouse model. This project will improve CKD classification and clinical management, reveal disease mechanisms as well as novel treatments. In a broader perspective, this project will set the stage for future clinical trials and for other RNA-based gene-specific CKD treatments.

Keywords: chronic kidney disease ckd,end stage kidney disease eskd,monogenic ckd,wdr19,umod,asos,genetic kidney disease